← Back to Search

Antibiotic

Xeruborbactam + Cefiderocol for Bacterial Infections

Phase 1
Waitlist Available
Research Sponsored by Qpex Biopharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female, 18 to 55 years of age at the time of signing the informed consent
Be between 18 and 65 years old
Must not have
History of any severe hypersensitivity, anaphylaxis, or allergic reaction to cefiderocol or any other beta-lactam antibacterial drugs, or any other excipients used in the formulation (eg, cephalosporins, penicillins, carbapenems, or monobactams)
Females who are pregnant or lactating
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 17 days
Awards & highlights

Summary

This trial will test the safety and how well cefiderocol works when combined with xeruborbactam in healthy adults.

Who is the study for?
This trial is for healthy adults who can participate in a study to understand how two drugs interact with each other. Specific eligibility details are not provided, but typically participants should have no significant health issues.
What is being tested?
The study tests the interaction between Xeruborbactam and Cefiderocol, both antibiotics, in healthy adults. It's randomized and placebo-controlled, meaning some people get the real drugs while others get an inactive substance without knowing which one they received.
What are the potential side effects?
Since this is a phase 1 trial primarily focused on safety and how the body processes the drugs (pharmacokinetics), potential side effects may include typical drug reactions such as nausea, headaches, allergic reactions or site-specific issues like pain where the drug was administered.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 55 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am allergic to certain antibiotics like penicillins or cephalosporins.
Select...
I am not pregnant or breastfeeding.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~17 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 17 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Area under the plasma concentration versus time curve (AUC) between cohorts
Number of patients with changes from baseline in safety parameters
Peak plasma Concentration measurements by subject and by cohort (Cmax)
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Single Dose CohortsExperimental Treatment3 Interventions
Administered single fixed dose of Xeruborbactam Administered single fixed dose of Cefiderocol Administered single fixed dose of a combination of Xeruborbactam and Cefiderocol.
Group II: Single Dose Cohorts PlaceboPlacebo Group1 Intervention
5% Dextrose in water
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cefiderocol
2020
Completed Phase 3
~1800

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Biomedical Advanced Research and Development AuthorityFED
88 Previous Clinical Trials
550,153 Total Patients Enrolled
Shionogi Inc.Industry Sponsor
9 Previous Clinical Trials
730 Total Patients Enrolled
Qpex Biopharma, Inc.Lead Sponsor
7 Previous Clinical Trials
417 Total Patients Enrolled
~27 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top